Want to see AU:MEM full AI Analyst Report?
Memphasys Ltd (MEM) AI Stock Analysis
Memphasys Ltd
(ASX:MEM)
The overall score is at the minimum threshold, reflecting a high-risk, pre-revenue biotechnology company. The most significant factor is the extremely weak financial performance, characterized by persistent cash burn and a shrinking equity base. This is compounded by a lack of technical data and negative valuation metrics, leaving no fundamental or market-based support for a higher score.
Memphasys Ltd (MEM) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 12.38M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -2.5
- Beta (1Y)
- 0.13
- Revenue Growth
- 7299.81%
- EPS Growth
- 39.29%
- Country
- Australia
- Employees
- 24
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Memphasys Ltd Business Overview & Revenue Model
Company Description
Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechnolo...
How the Company Makes Money
Memphasys’ intended revenue model is primarily based on commercialising its reproductive technology device platform, led by the Felix System, for use by fertility clinics and ART providers. In practice, the company can generate revenue through (i) di...
Memphasys Ltd Financial Statement Overview
Summary
Financial health is critically weak. The company is burning cash with deeply negative free cash flow, net losses are persistent, and shareholders' equity is eroding rapidly. While revenue growth has shown volatility with a recent 28% jump, the inability to achieve profitability or positive cash flow presents a significant viability risk.
Income Statement
35NegativeBalance Sheet
45NeutralCash Flow
25Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 273.79K | 273.79K | 526.92K | 60.00K | 15.37K | 27.15K |
| Gross Profit | -1.52M | -1.52M | 431.06K | -1.57M | -824.86K | -922.60K |
| EBITDA | -3.56M | -3.56M | -2.57M | -4.24M | -2.36M | -1.39M |
| Net Income | -4.10M | -4.10M | -4.94M | -4.44M | -3.40M | -2.08M |
Balance Sheet | ||||||
| Total Assets | 11.24M | 11.24M | 11.02M | 12.43M | 14.67M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.18M | 1.18M | 298.30K | 277.80K | 637.83K | 311.83K |
| Total Debt | 4.24M | 4.24M | 5.11M | 4.81M | 6.37M | 5.56M |
| Total Liabilities | 7.02M | 7.02M | 5.65M | 5.59M | 7.28M | 6.47M |
| Stockholders Equity | 4.21M | 4.21M | 5.37M | 6.84M | 7.38M | 7.65M |
Cash Flow | ||||||
| Free Cash Flow | -2.49M | -2.49M | -2.41M | -3.87M | -3.23M | -2.61M |
| Operating Cash Flow | -2.49M | -2.49M | -2.41M | -3.23M | -1.41M | 311.82K |
| Investing Cash Flow | -3,379 | -3,379 | -673.28K | -711.05K | -1.98M | -3.08M |
| Financing Cash Flow | 3.37M | 3.37M | 3.15M | 3.54M | 3.75M | 1.03M |
Memphasys Ltd Peers Comparison
Overall Rating
AU:CTE61Neutral
AU:MVF53.5Neutral
AU:PGC50Neutral
AU:AT145Neutral
AU:GSS39Underperform- AU:MEM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:CTE | 61Neutral | AUD 59.55M | 26.64 | 52.84% | ― | 18.31% | 18.65% |
| AU:MVF | 54Neutral | AUD 280.54M | 37.70 | 2.95% | 3.47% | -0.90% | -70.25% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:PGC | 50Neutral | AUD 256.57M | -16.14 | -5.34% | ― | 1.84% | -178.23% |
| AU:AT1 | 45Neutral | AUD 12.63M | -3.33 | -48.97% | ― | 40.65% | 45.45% |
| AU:GSS | 39Underperform | AUD 17.72M | -1.27 | -35.10% | ― | -9.10% | 31.75% |
| AU:MEM | 37Underperform | AUD 12.38M | -2.50 | -99.67% | ― | 7299.81% | 39.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:MEM | Memphasys Ltd | ― | ― | ― | |
| AU:PGC | Paragon Care Limited | 0.15 | -0.17 | -51.56% | |
| AU:AT1 | Atomo Diagnostics Ltd. | 0.01 | -0.02 | -53.33% | |
| AU:CTE | Cryosite Limited | 1.22 | 0.02 | 1.67% | |
| AU:GSS | Genetic Signatures Ltd. | 0.08 | -0.22 | -73.56% | |
| AU:MVF | Monash IVF Group Ltd | 0.72 | 0.05 | 8.11% |
Memphasys Ltd Corporate Events
Memphasys to Brief Investors on Global Rollout of Felix Fertility Device
Memphasys Limited has invited shareholders to an investor webinar titled Lynx Discovery Series: Health Innovation, where Non-Executive Director and Commercialisation Committee Chair Marjan Mikel will provide an update on the company and its Felix Sys...
Memphasys Wins Turkish Approval for Felix System, Launches Commercial Sales
Memphasys Limited has secured product registration for its Felix System in Turkey, allowing exclusive regional partner ITL to begin commercial sales of Felix cartridges and consoles in the country. An initial order of 100 cartridges and two consoles...
Memphasys Options Lapse, Trimming Potential Future Dilution
Memphasys Limited has announced the cessation of 31,250,000 MEMAW listed options, which carried an exercise price of $0.011 and an expiry date of 28 August 2026. The options lapsed without being exercised or converted, resulting in their removal from...
Memphasys Seals €526,500 Nordic Deal to Grow Felix™ in Europe
Memphasys Limited has signed an exclusive commercialisation agreement with Denmark-based NOVIVITAE ApS to distribute the Felix™ System across Denmark, Sweden, Norway, Finland and Iceland. The deal adds the Nordic states to existing arrangements...
Memphasys Narrows Loss as Felix Sales Scale but Auditor Flags Going Concern Risk
Memphasys Ltd reported a narrowed audited net loss of $4.1 million for the year to 30 June 2026, down from $5.0 million a year earlier, with underlying EBITDA improving to a loss of $3.2 million from $3.8 million. The company did not declare any divi...
Memphasys Accelerates Felix Launch After Early Thai FDA Approval
Memphasys Limited has secured early approval from the Thai Food and Drug Administration for its Felix System, clearing the way for commercial sales across Thailand under an exclusive three-year distribution agreement with IVF Envimed. The deal, with...
Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order
Memphasys Ltd, an Australian reproductive biotech specialist, is commercialising its Felix System, a patented sperm selection technology designed to improve outcomes in assisted reproduction and reduce lab time. The system aims to displace convention...
Memphasys builds momentum as Felix sperm selection system gains clinical and commercial traction
Memphasys has showcased pivotal clinical data for its Felix sperm selection system to a major scientific audience at the Fertility Society of Australia and New Zealand 2026 conference, highlighting superior embryo utilisation rates compared with dens...
Memphasys Plans 8 Million-Share Placement on ASX
Memphasys Limited, trading on the ASX as MEM, is a biotechnology and medical technology company focused on reproductive and life-science solutions. Its capital structure is based on ordinary fully paid shares listed on the Australian Securities Excha...
Memphasys Moves General Meeting Online and Shifts to Digital Shareholder Communication
Memphasys Limited has called a virtual General Meeting of shareholders for 21 August 2026, to be held via webinar at 2:00pm AEST, with shareholders encouraged to lodge proxy forms in advance. The company is leveraging recent changes to the Corporatio...
Memphasys Deepens Director’s Role with New Executive Consulting Agreement
Memphasys Limited has entered into a consulting agreement with Mikel Enterprises Pty Ltd, an entity associated with director Marjan Mikel, under which Mr Mikel will take on an executive consulting role. He will provide strategic advisory services acr...
Memphasys seals exclusive Thailand Felix deal, lifting FY2026 contracted revenue
Memphasys has signed an exclusive three-year distribution agreement with Bangkok-based IVF Envimed for its Felix sperm separation system in Thailand, a market of 110 registered IVF clinics performing an estimated 20,000 to 30,000 IVF cycles annually....
Memphasys Issues 240 Million Shares to Fund Growth of Fertility Technology
Memphasys Limited has issued 240,000,000 fully paid ordinary shares at $0.005 each to sophisticated and professional investors as part of a placement previously announced to the market. The company confirms the shares were issued without a prospectus...
Memphasys seeks ASX quotation for 240 million new shares
Memphasys Ltd has applied for quotation on the ASX of 240 million new ordinary fully paid shares, with an issue date of June 26, 2026. The application, lodged as a new announcement under Appendix 2A, follows previously notified transactions and signa...
Memphasys accelerates UK IVF rollout of Felix System after rapid clinic uptake
Memphasys has accelerated its commercial rollout in the United Kingdom, one of the world’s largest IVF markets, with four IVF groups now actively commercial trialling the Felix System and initial orders placed within weeks of first engagement....
Memphasys Secures Landmark Monash IVF Deal to Drive Global Expansion
Memphasys has secured the largest commercial agreement in its history with Monash IVF, anchoring a new phase of commercial execution for its fertility technology platform. The deal underpins a recurring revenue model built around consoles and single-...
Memphasys to brief investors on global rollout of Felix System and growth plans
Memphasys Limited will host an investor webinar on 24 June 2026 to update shareholders on its commercial progress, regulatory achievements and growth trajectory as it advances global rollout of the Felix System and a recurring cartridge revenue model...
Memphasys Plans Major Share and Options Issue on ASX
Memphasys Limited has notified the ASX of a proposed capital raising via a placement or other type of securities issue. The company plans to issue up to 240,000,000 fully paid ordinary shares and 2,500,000 unlisted options, with the issue date target...
Memphasys raises $1.2m and extends note as Felix rollout accelerates
Memphasys Limited has raised $1.2 million via a share placement at $0.005 per share, fully utilising its existing placement capacity, to fund the commercial rollout of its Felix sperm separation system and build inventory for rising demand. The raise...
Memphasys seals exclusive national Felix™ supply deal with Monash IVF
Memphasys has signed a 12‑month exclusive national supply agreement with Monash IVF Group for its Felix™ automated sperm selection system, following inclusion of the device on the Australian Register of Therapeutic Goods. The deal, which...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026